Recent advances on radionuclide labeled hypoxia-imaging agents

Current Pharmaceutical Design

Volumn 18, Issue 8, 2012, Pages 1084-1097

  Li, Zejun ^a   Chu, Taiwei ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

Hypoxia imaging agent; Nitroimidazole; Radionuclide; Redox sensitive compounds; Tumor

Indexed keywords

1 (4 NITROIMIDAZOL 1 YL)PROPANHYDROXYIMINOAMIDE TC 99M; 1 [2 FLUORO 1 (HYDROXYMETHYL)ETHOXY]METHYL 2 NITROIMIDAZOLE F 18; 1 ALPHA DEXTRO (2 DEOXY 2 FLUORORIBOFURANOSYL) 2 NITROIMIDAZOLE F 18; 1 ALPHA DEXTRO(5 DEOXY 5 FLUOROARABINOFURANOSYL) 2 NITROIMIDAZOLE F 18; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 2 METHYL 5 NITROIMIDAZOLE; 2 NITROIMIDAZOLE; 3 FLUORO 2 [4 [(2 NITRO 1H IMIDAZOL 1 YL)METHYL] 1H 1,2,3 TRIAZOL 1 YL]PROPAN 1 OL F 18; 4 NITROIMIDAZOLE; AMYLOID BETA PROTEIN; BRU 59 21; CARBONATE DEHYDRATASE IX; CHELATING AGENT; FLUOROETANIDAZOLE F 18; GALLIUM 68; HYPOXIA IMAGING AGENT; HYPOXIA INDUCIBLE FACTOR 1; IODOAZOMYCIN GALACTOPYRANOSIDE I 124; IODOAZOMYCIN GALACTOSIDE I 124; N [4 (BENZOTHIAZOL 2 YL)PHENYL] 11 (2 NITROIMIDAZOL 1 YL)UNDECANAMIDE I 131; N [4 (BENZOTHIAZOL 2 YL)PHENYL] 3 (2 NITROIMIDAZOL 1 YL)PROPANAMIDE I 131; N [4 (BENZOTHIAZOL 2 YL)PHENYL] 3 (4 NITROIMIDAZOL 1 YL) N METHYLPROPANAMIDE I 131; N [4 (BENZOTHIAZOL 2 YL)PHENYL] 3 (4 NITROIMIDAZOL 1 YL)PROPANAMIDE I 131; OXO[3,3,9,9 TETRAMETHYL 1 (2 NITRO 1H IMIDAZOL 1 YL) 4,8 DIAZAUNDECANE 2,10 DIONEDIOXIMATO]TECHNETIUM TC 99M; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; THIOFLAVINE; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; CANCER DIAGNOSIS; CANCER STAGING; CHEMICAL STRUCTURE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG SOLUBILITY; DRUG SYNTHESIS; DRUG TUMOR LEVEL; ERYTHROCYTE; GLIOBLASTOMA; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HEMANGIOBLASTOMA; HUMAN; HYPOXEMIA; IMAGE ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LIPOPHILICITY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MOLECULAR IMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK; TUMOR CELL;

ANIMALS; BIOLOGICAL MARKERS; CELL HYPOXIA; DRUG DESIGN; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84863129496     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799315849     Document Type: Article

References (110)

1. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med 2008; 49: 129S-48S.
2. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 2008; 8: 705-13.
3. Mees G, Dierckx R, Vangestel C, Van de Wiele C. Molecular imaging of hypoxia with radiolabelled agents. Eur J Nucl Med Mol Imaging 2009; 36: 1674-86.
4. Chitneni SK, Palmer GM, Zalutsky MR, Dewhirst MW. Molecular Imaging of Hypoxia. J Nucl Med 2011; 52: 165-8.
5. Fang SW, Hong MT, Zhang H. Positron Emission Tomography Imaging of Tumor Hypoxia. Curr Med Imaging Rev 2010; 6: 8-16.
6. Melo T, Duncan J, Ballinger JR, Rauth AM. BRU59-21, a secondgeneration Tc-99m-labeled 2-nitroimidazole for imaging hypoxia in tumors. J Nucl Med 2000; 41: 169-76.
7. 99mTc(CO)3-labeled 2- nitro 4-nitroimidazole. J Label Compd Radiopharm 2008; 51: 308-13.
8. 3 complexes to target hypoxic tumors. J Label Compd Radiopharm 2010; 53: 535-42.
9. Chu TW, Li RJ, Hu SW, Liu XQ, Wang XY. Preparation and biodistribution of technetium-99m-labeled 1-(2-nitroimidazole-1-yl)- propanhydroxyimino amide (N2IPA) as a tumor hypoxia marker. Nucl Med Biol 2004; 31: 199-203.
10. Mannan RH, Somayaji VV, Jane Lee J, Mercer JR, Chapman JD, and Wiebe LI. Radioiodinated 1-(5-Iodo-5-deoxy-β-Darabinofuranosyl)-2-nitroimidazole (Iodoazomycin Arabinoside: IAZA): A Novel Marker of Tissue Hypoxia. J Nucl Med 1991; 32: 1764-70.
11. Kumar P, Ohkura K, Beiki D, Wiebe LI, Seki K. Synthesis of 1- beta-D-(5-deoxy-5-iodoarabinofuranosyl)-2-nitroimidazole (beta- IAZA): A novel marker of tissue hypoxia. Chem Pharm Bull 2003; 51: 399-403.
12. Zanzonico P, O'Donoghue J, Chapman JD, et al. Iodine-124- labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning. Eur J Nucl Med Mol Imaging 2004; 31: 117-28.
13. 18F]FAZA - First small animal PET results. J Pharm Pharm Sci 2007; 10: 203-11.
14. Riedl CC, Brader P, Zanzonico PB, et al. Imaging hypoxia in orthotopic rat liver tumors with iodine 124-labeled iodoazomycin galactopyranoside PET. Radiology 2008; 248: 561-70.
15. Mathis CA, Bacskai BJ, Kajdasz ST, et al. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett 2002; 12: 295-8.
16. Li ZJ, Chu TW, Liu XQ, Wang XY. Synthesis and in vitro and in vivo evaluation of three radioiodinated nitroimidazole analogues as tumor hypoxia markers. Nucl Med Biol 2005; 32: 225-31.
17. Chu TW, Li ZJ, Liu XQ, Wang XY. In vivo Evaluation of the Nitroimidazole- Based Thioflavin-T Derivatives as Cerebral Ischemia Markers. Int J Biomed Imaging 2007; 49791.
18. Chu TW, Li ZJ, Wang XY. Synthesis and biological evaluation of radioiodinated 2NUBTA as a cerebral ischemia marker. Bioorg Med Chem Lett 2009; 19: 658-61.
19. West CML, Charnley N. The potential of PET to increase understanding of the biological basis of tumour and normal tissue response to radiotherapy. Br J Radiol 2005; Suppl 28: 50-4.
20. 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005; 46: 253-60.
21. 15O-H2O. J Nucl Med 2004; 45: 1851-9.
22. Kaneta T, Takai Y, Iwata R, et al. Initial evaluation of dynamic human imaging using F-18-FRP170 as a new PET tracer for imaging hypoxia. Ann Nucl Med 2007; 21: 101-7.
23. Postema EJ, McEwan AJB, Riauka TA, et al. Initial results of hypoxia imaging using 1-alpha-D-(5-deoxy-5-[F-18]-fluoroarabinofuranosyl)-2-nitroimidazole (F-18-FAZA). Eur J Nucl Med Mol Imaging 2009; 36: 1565-73.
24. Bouvet VR, Wuest M, Wiebe LI, Wuest F. Synthesis of hypoxia imaging agent 1-(5-deoxy-5-fluoro-alpha-D-arabinofuranosyl)-2- nitroimidazole using microfluidic technology. Nucl Med Biol 2011; 38: 235-45.
25. Kumar P, Naimi E, McEwan AJ, Wiebe LI. Synthesis, radiofluorination, and hypoxia-selective studies of FRAZ: A configurational and positional analogue of the clinical hypoxia marker, [F-18]- FAZA. Bioorg Med Chem 2010; 18: 2255-64.
26. 18F-EF5. Eur J Nucl Med Mol Imaging 2003; 30: 259-66.
27. Komar G, Seppanen M, Eskola O, et al. F-18-EF5: A New PET Tracer for Imaging Hypoxia in Head and Neck Cancer. J Nucl Med 2008; 49: 1944-51.
28. van Loon J, Janssen MHM, Ollers M, et al. PET imaging of hypoxia using [F-18]HX4: a phase I trial. Eur J Nucl Med Mol Imaging 2010; 37: 1663-8.
29. Rasey JS, Hofstrand PD, Chin LK, Tewson TJ. Characterization of [18F]Fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia. J Nucl Med 1999; 40: 1072-9.
30. Barthel H, Wilson H, Collingridge DR, et al. In vivo evaluation of [F-18]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography. Br J Cancer 2004; 90: 2232-42.
31. Hoigebazar L, Jeong JM, Choi SY, et al. Synthesis and Characterization of Nitroimidazole Derivatives for Ga-68-Labeling and Testing in Tumor Xenografted Mice. J Med Chem 2010; 53: 6378-85.
32. Chu TW, Hu SW, Wei B, et al. Synthesis and biological results of the technetium-99m-labeled 4-nitroimidazole for imaging tumor hypoxia. Bioorg Med Chem Lett 2004; 14: 747-9.
33. Chu TW, Xu H, Yang Z, Wang XY. Synthesis and in vitro evaluation of three Tc-99m-labeled hydroxamamide-based ligands as markers for hypoxic cells. Appl Radiat Isot 2009; 67: 590-3.
34. Xu H, Chu TW, Wang XG, Liu XQ. Facile synthesis of bis(hydroxamamide)-based tetradentate ligands for Tc-99mradiopharmaceutical. Appl Radiat Isot 2005; 62: 919-22.
35. Mallia MB, Subramanian S, Mathur A, Sarma HD, Venkatesh M, Banerjee S. On the isolation and evaluation of a novel unsubstituted 5-nitroimidazole derivative as an agent to target tumor hypoxia. Bioorg Med Chem Lett 2008; 18: 5233-7.
36. Liu LQ, Zhang M, Zhong GR, Wang XB. Synthesis and biodistribution of a novel Tc-99m complex of HYNIC-conjugated metronidazole as a potential tumor hypoxia imaging agent. J Radioanal Nucl Chem 2011; 287: 847-52.
37. Kong DJ, Lu J, Ye SZ, Wang XB. Synthesis and biological evaluation of a novel asymmetrical Tc-99m-nitrido complex of metronidazole derivative. J Label Compd Radiopharm 2007; 50: 1137-42.
38. 3 complex of 2-methyl-5-nitroimidazole as an agent for targeting tumor hypoxia. Bioorg Med Chem 2006; 14: 7666-70.
39. Bejot R, Kersemans V, Kelly C, Carroll L, King RC, Gouverneur V. Pre-clinical evaluation of a 3-nitro-1,2,4-triazole analogue of [F-18]FMISO as hypoxia-selective tracer for PET. Nucl Med Biol 2010; 37: 565-75.
40. Zhang Y, Chu TW, Gao XG, et al. Synthesis and preliminary biological evaluation of the Tc-99m labeled nitrobenzoimidazole and nitrotriazole as tumor hypoxia markers. Bioorg Med Chem Lett 2006; 16: 1831-3.
41. Murugesan S, Shetty SJ, Noronha OPD, et al. Technetium-99mcyclam AK 2123: a novel marker for tumor hypoxia. Appl Radiat Isot 2001; 54: 81-8.
42. Giglio J, Patsis G, Pirmettis I, et al. Preparation and characterization of technetium and rhenium tricarbonyl complexes bearing the 4-nitrobenzyl moiety as potential bioreductive diagnostic radiopharmaceuticals. In vitro and in vivo studies. Eur J Med Chem 2008; 43: 741-8.
43. Giglio J, Rey A, Cerecetto H, et al. Design and evaluation of "3+1" mixed ligand oxorhenium and oxotechnetium complexes bearing a nitroaromatic group with potential application in nuclear medicine oncology. Eur J Med Chem 2006; 41: 1144-52.
44. Cerecetto H, Gonzalez M, Onetto S, et al. Synthesis and characterization of thiol containing furoxan derivatives as coligands for the preparation of potential bioreductive radiopharmaceuticals. Arch Pharm 2006; 339: 59-66.
45. Cook GJR, Houston S, Barrington SF and Fogelman I. Technetium-99m-Labeled HL91 to Identify Tumor Hypoxia: Correlation with Fluorine-18-FDG. J Nucl Med 1998; 39: 99-103.
46. 99mTc- BnAO (HL-91): a non-nitroaromatic compound for hypoxic cell detection. Int J Radiat Oncol Biol Phys 1998; 42: 737-40.
47. Lee BF, Chiu NT, Hsia CC, Shen LH. Accumulation of Tc-99m HL91 in tumor hypoxia: in vitro cell culture and in vivo tumor model. Kaohsiung J Med Sci 2008; 24: 461-72.
48. Hsia CC, Huang FL, Lin CH, Shen LH, Wang HE. The preparation and biological characterization of a new HL91-derivative for hypoxic imaging on stroke mice. Appl Radiat Isot 2010; 68: 1610-15.
49. Sun X, Chu TW, Wang XY. Preliminary studies of 99mTc-BnAO and its analogues: synthesis, radiolabeling and in vitro cell uptake. Nucl Med Biol 2010; 37: 117-23.
50. Li L, Xu Y, Su ZF. The correlation of serum protein association and cellular uptake with lipophilicity and polarity of the backbone substituents of the technetium-99m-amine-oxime chelates. J Label Compd Radiopharm 2007; 50: 91-5.
51. 99mTc labeled amine-oxime (AO) complexes. Theor Chem Acc 2008; 121: 271-8.
52. Wood KA, Wong WL, Saunders MI. [Cu-64]diacetyl-bis(N-4- methyl-thiosemicarbazone) - a radiotracer for tumor hypoxia. Nucl Med Biol 2008; 35: 393-400.
53. McQuade P, Martin KE, Castle TC, et al. Investigation into Cu-64- labeled Bis(selenosemicarbazone) and Bis(thiosemicarbazone) complexes as hypoxia imaging agents. Nucl Med Biol 2005; 32: 147-56.
54. Carroll L, Bejot R, Hueting R, et al. Orthogonal F-18 and Cu-64 labelling of functionalised bis(thiosemicarbazonato) complexes. Chem Commun 2010; 46: 4052-4.
55. Bayly SR, King RC, Honess DJ, et al. In vitro and In vivo Evaluations of a Hydrophilic Cu-64-Bis(Thiosemicarbazonato)-Glucose Conjugate for Hypoxia Imaging. J Nucl Med 2008; 49: 1862-8.
56. Blower PJ, Went MJ, Martin KE, Smith GE. Imaging hypoxia in vivo by controlling the electrochemistry of copper radionuclide complexes. J Label Compd Radiopharm 2007; 50: 354-9.
57. Dearling JLJ, Lewis JS, Muller GED, Welch MJ, Blower PJ. Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. J Biol Inorg Chem 2002; 7: 249-59.
58. Maurer RI, Blower PJ, Dilworth JR, Reynolds CA, Zheng YF, Mullen GED Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals. J Med Chem 2002; 45: 1420-31.
59. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997; 38: 1155-60.
60. Dearling JLJ, Packard AB. Some thoughts on the mechanism of cellular trapping of Cu(II)-ATSM. Nucl Med Biol 2010; 37: 237-43.
61. Holland JP, Barnard PJ, Collison D, et al. Spectroelectrochemical and computational studies on the mechanism of hypoxia selectivity of copper radiopharmaceuticals. Chem-Eur J 2008; 14: 5890-7.
62. Holland JP, Green JC, Dilworth JR Probing the mechanism of hypoxia selectivity of copper bis(thiosemicarbazonato) complexes: DFT calculation of redox potentials and absolute acidities in solution. Dalton Trans 2006; 6: 783-94.
63. Holland JP, Giansiracusa JH, Bell SG, Wong LL, Dilworth JR. In vitro kinetic studies on the mechanism of oxygen-dependent cellular uptake of copper radiopharmaceuticals. Phys Med Biol 2009; 54: 2103-19.
64. Castle TC, Maurer RI, Sowrey FE, et al. Hypoxia-targeting copper bis(selenosemicarbazone) complexes: Comparison with their sulfur analogues. J Am Chem Soc 2003; 125: 10040-9.
65. Rami M, Winum JY, Innocenti A, Montero JL, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors: Copper(II) complexes of polyamino-polycarboxylamido aromatic/heterocyclic sulfonamides are very potent inhibitors of the tumor-associated isoforms IX and XII. Bioorg Med Chem Lett 2008; 18: 836-41.
66. Rami M, Cecch A, Montero JL, et al. Carbonic Anhydrase Inhibitors: Design of Membrane-Impermeant Copper(II) Complexes of DTPA-, DOTA-, and TETA-Tailed Sulfonamides Targeting the Tumor-Associated Transmembrane Isoform IX. ChemMedChem 2008; 3: 1780-8.
67. 124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 2007; 8: 304-10.
68. Carlin S, Khan N, Ku T, Longo VA, Larson SM, Smith-Jones PM. Molecular Targeting of Carbonic Anhydrase IX in Mice with Hypoxic HT29 Colorectal Tumor Xenografts. PLoS One 2010; 5: e10857.
69. Askoxylakis V, Garcia-Boy R, Rana S, et al. A New Peptide Ligand for Targeting Human Carbonic Anhydrase IX, Identified through the Phage Display Technology. PLoS One 2010; 5: e15962.
70. Ahlskog JKJ, Schliemann C, Marlind J, et al. Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours. Br J Cancer 2009; 101: 645-57.
71. Kudo T, Ueda M, Kuge Y, et al. Imaging of HIF-1-Active Tumor Hypoxia Using a Protein Effectively Delivered to and Specifically Stabilized in HIF-1-Active Tumor Cells. J Nucl Med 2009; 50: 942-9.
72. Ueda M, Kudo T, Kuge Y, et al. Rapid detection of hypoxiainducible factor-1-active tumours: pretargeted imaging with a protein degrading in a mechanism similar to hypoxia-inducible factor-1 alpha. Eur J Nucl Med Mol Imaging 2010; 37: 1566-74.
73. Holland JP, Aigbirhio FI, Betts HM, et al. Functionalized Bis(thiosemicarbazonato) Complexes of Zinc and Copper: Synthetic Platforms Toward Site-Specific Radiopharmaceuticals. Inorg Chem 2007; 46: 465-85.
74. Bonnitcha PD, Bayly SR, Theobald MBM, Betts HM, Lewis JS, Dilworth JR. Nitroimidazole conjugates of bis(thiosemicarbazonato) Cu-64(II) - Potential combination agents for the PET imaging of hypoxia. J Inorg Biochem 2010; 104: 126-35.
75. Hsia CC, Huang FL, Hung GU, Shen LH, Chen CL, Wang HE. The biological characterization of Tc-99m-BnAO-NI as a SPECT probe for imaging hypoxia in a sarcoma-bearing mouse model. Appl Radiat Isot 2011; 69: 649-55.
76. Pascu SI, Waghorn PA, Kennedy BWC, et al. Fluorescent Copper(II) Bis(thiosemicarbazonates): Synthesis, Structures, Electron Paramagnetic Resonance, Radiolabeling, In vitro Cytotoxicity and Confocal Fluorescence Microscopy Studies. Chem-Asian J 2010; 5: 506-19.
77. Lim SC, Price KA, Chong SF, et al. Copper and zinc bis(thiosemicarbazonato) complexes with a fluorescent tag: synthesis, radiolabelling with copper-64, cell uptake and fluorescence studies. J Biol Inorg Chem 2010; 15: 225-35.
78. 18F]trifluoroethylation reveals a striking difference between trifluoroethyl tosylate and iodide in regiochemical reactivity toward oxygen nucleophiles. Bioorg Med Chem 2011; 19: 2287-97.
79. Zhang X, Su ZF, Ballinger JR, Rauth AM, Pollak A, Thornback JR. Targeting Hypoxia in Tumors Using 2-Nitroimidazoles with Peptidic Chelators for Technetium-99m: Effect of Lipophilicity. Bioconjugate Chem 2000; 11: 401-7.
80. Chapman JD, Engelhardt EL, Stobbe CC, Schneider RF, Hanks GE. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother Oncol 1998; 46: 229-37.
81. Burgman P, O'Donoghue JA, Lewis JS, Welch MJ, Humm JL, Ling CC. Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM. Nucl Med Biol 2005; 32: 623-30.
82. 2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 2005; 61: 1493-502.
83. Vavere AL, Lewis JS. Examining the relationship between Cu- ATSM hypoxia selectivity and fatty acid synthase expression in human prostate cancer cell lines. Nucl Med Biol 2008; 35: 273-9.
84. Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, Dewhirst MW. Intertumoral differences in hypoxia selectivity of the PET imaging agent Cu-64(II)-diacetyl-bis(N-4-methylthiosemicarbazone). J Nucl Med 2006; 47: 989-98.
85. Li XF, Sun XR, Ma YY, et al. Detection of hypoxia in microscopic tumors using I-131-labeled iodo-azomycin galactopyranoside (I-131-IAZGP) digital autoradiography. Eur J Nucl Med Mol Imaging 2010; 37: 339-48.
86. Suehiro M, Burgman P, Carlin S, et al. Radiosynthesis of [I-131]IAZGP via nucleophilic substitution and its biological evaluation as a hypoxia marker - is specific activity a factor influencing hypoxia-mapping ability of a hypoxia marker? Nucl Med Biol 2009; 36: 477-87.
87. 18F]fluoromisonidazole uptake in experimental mouse tumours. Eur J Nucl Med Mol Imaging 2006; 33: 311-8.
88. Parliament MB, Wiebe LI, Franko AJ. Nitroimidazole adducts as markers for tissue hypoxia: mechanistic studies in aerobic normal tissues and tumour cells. Br J Cancer 1992; 66: 1103-8.
89. Matsumoto KI, Szajek L, Krishna MC, et al. The influence of tumor oxygenation on hypoxia imaging in murine squamous cell carcinoma using [Cu-64]Cu-ATSM or [F-18]Fluoromisonidazole positron emission tomography. Int J Oncol 2007; 30: 873-81.
90. Liu J, Hajibeigi A, Ren G, et al. Retention of the Radiotracers Cu-64-ATSM and Cu-64-PTSM in Human and Murine Tumors Is Influenced by MDR1 Protein Expression. J Nucl Med 2009; 50: 1332-9.
91. Yoshii Y, Furukawa T, Kiyono Y, et al. Copper-64-diacetyl-bis (N-4-methylthiosemicarbazone) accumulates in rich regions of CD133(+) highly tumorigenic cells in mouse colon carcinoma. Nucl Med Biol 2010; 37: 395-404.
92. Xiao ZG, Donnelly PS, Zimmermann M, Wedd AG. Transfer of copper between bis(thiosemicarbazone) ligands and intracellular copper-binding proteins. Insights into mechanisms of copper uptake and hypoxia selectivity. Inorg Chem 2008; 47: 4338-47.
93. Chong LX, Ash MR, Maher MJ, Hinds MG, Xiao ZG, Wedd AG. Unprecedented Binding Cooperativity between Cu-I and Cu-II in the Copper Resistance Protein CopK from Cupriavidus metallidurans CH34: Implications from Structural Studies by NMR Spectroscopy and X-Ray Crystallography. J Am Chem Soc 2009; 131: 3549-64.
94. Rubino JT, Chenkin MP, Keller M, Riggs-Gelasco P, Franz KJ. A comparison of methionine, histidine and cysteine in copper(I)- binding peptides reveals differences relevant to copper uptake by organisms in diverse environments. Metallomics 2011; 3: 61-73.
95. Basken NE, Mathias CJ, Lipka AE, Green MA. Species dependence of [Cu-64]Cu-Bis(thiosemicarbazone) radiopharmaceutical binding to serum albumins. Nucl Med Biol 2008; 35: 281-6.
96. Hendrickson K, Phillips M, Smith W, Peterson L, Krohn K, Rajendran J. Hypoxia imaging with [F-18]FMISO-PET in head and neck cancer: Potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance. Radiother Oncol 2011; 101: 369-75.
97. Toma-Dasu I, Uhrdin J, Antonovic L, et al. Dose prescription and treatment planning based on FMISO-PET hypoxia. Acta Oncol 2011; in press and available online.
98. 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma. Ann Nucl Med 2011; 25: 625-33.
99. 18fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study. Radiother Oncol 2011; 98: 109-16.
100. 18F-fluoromisonidazole PET/CT study. J Nucl Med 2011; 52: 1048-55.
101. 18F]-FMISO-PET images. Math Med Biol 2011; in press and available online.
102. 18F-fluoromisonidazole PET in newly diagnosed glioblastoma. Eur J Nucl Med Mol Imaging 2011; 38: 441-50.
103. Spratt NJ, Donnan GA, McLeod DD, Howells DW. 'Salvaged' stroke ischaemic penumbra shows significant injury: studies with the hypoxia tracer FMISO. J Cereb Blood Flow Metab 2011; 31: 934-43.
104. Vallabhajosula S, Solnes L, Vallabhajosula B. A broad overview of positron emission tomography radiopharmaceuticals and clinical applications: what is new? Semin Nucl Med 2011; 41: 246-64.
105. Imam SK. Review of positron emission tomography tracers for imaging of tumor hypoxia. Cancer Biother Radiopharm. 2010; 25: 365-74.
106. 60Cu-ATSM in cancer of the uterine cervix. Mol Imaging Biol 2007; 9: 278-83.
107. 60Cu-ATSM in cancer of the uterine cervix. J Nucl Med 2008; 49: 1177-82.
108. 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum 2008; 51: 1641-8.
109. 62Cu-ATSM PET/CT as a predictor of response in head and neck cancer: a pilot study. Ann Nucl Med 2011; 25: 339-45.
110. 18F-FDG in lung cancer. J Nucl Med 2009; 50: 1948-53.